{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:53:44Z","timestamp":1780541624708,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Previous studies have shown that reducing drug-related problems (DRPs) may improve therapeutic outcomes in patients with Parkinson\u2019s disease (PD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>To investigate the impact of pharmacist participation in Parkinson\u2019s disease clinic on the number of DRPs, clinical outcomes, and the quality of life of PD patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>This single-blinded randomised controlled trial was conducted at the Parkinson\u2019s Disease and Movement Disorders Clinic. Patients aged\u2009\u2265\u200918\u00a0years, diagnosed with idiopathic PD for at least 3\u00a0years, and receiving antiparkinsonian drugs were randomly assigned (1:1) to the pharmacist-physician (PP) or usual care (UC) groups. The primary outcome was changes in the number of DRPs from baseline to 24\u00a0weeks between groups. Secondary outcomes included the Movement Disorder Society-Sponsored Revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS) score, eight-item version of the Parkinson\u2019s Disease Questionnaire (PDQ-8) score, and Patients\u2019 Global Impression of Change (PGIC) score at week 24.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 80 patients were randomised, with 40 in each group. The mean number of DRPs reduced in both groups; however, the reduction was greater in the PP group compared to the UC group (\u2212\u20097.2\u2009\u00b1\u20093.6 vs. \u2212\u20093.0\u2009\u00b1\u20091.8, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), especially non-adherence issues. The MDS-UPDRS and PDQ-8 scores showed significantly greater improvement in the PP group. A higher proportion of patients in the PP group achieved improvement in PGIC scales compared to those in the UC group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our findings demonstrated that pharmacist-physician collaboration service in the PD clinic positively impacted patient outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ClinicalTrials.gov NCT05410210 (date 13 May 2022).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11096-025-01883-6","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T12:04:30Z","timestamp":1739448270000},"page":"834-843","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of pharmacist-physician collaboration on patient outcomes in Parkinson\u2019s disease: a randomised controlled trial in tertiary care"],"prefix":"10.1007","volume":"47","clinical-trial-number":[{"clinical-trial-number":"nct05410210","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4144-0928","authenticated-orcid":false,"given":"Phanutgorn","family":"Techa-angkoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3741-340X","authenticated-orcid":false,"given":"Yuvadee","family":"Pitakpatapee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1386-1147","authenticated-orcid":false,"given":"Weerawat","family":"Saengphatrachai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1391-623X","authenticated-orcid":false,"given":"Prachaya","family":"Srivanitchapoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4390-0629","authenticated-orcid":false,"given":"Thanarat","family":"Suansanae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"issue":"9996","key":"1883_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386(9996):896\u2013912.","journal-title":"Lancet"},{"issue":"3","key":"1883_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","volume":"5","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Healy DG, Schapira AH. National Institute for Clinical Excellence. Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235\u201345.","journal-title":"Lancet Neurol."},{"issue":"6","key":"1883_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/jnnp-2019-322379","volume":"91","author":"A Schrag","year":"2020","unstructured":"Schrag A, Quinn N. What contributes to quality of life in Parkinson\u2019s disease: a re-evaluation. J Neurol Neurosurg Psychiatry. 2020;91(6):563\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"1883_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.2146\/ajhp110127","volume":"69","author":"LH Poon","year":"2012","unstructured":"Poon LH, Lee AJ, Chiao TB, et al. Pharmacist\u2019s role in a Parkinson\u2019s disease and movement disorders clinic. Am J Health Syst Pharm. 2012;69(6):518\u201320.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"1883_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40263-014-0220-0","volume":"29","author":"N Malek","year":"2015","unstructured":"Malek N, Grosset DG. Medication adherence in patients with Parkinson\u2019s disease. CNS Drugs. 2015;29(1):47\u201353.","journal-title":"CNS Drugs"},{"issue":"4","key":"1883_CR6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s11096-011-9526-x","volume":"33","author":"S Schr\u00f6der","year":"2011","unstructured":"Schr\u00f6der S, Martus P, Odin P, et al. Drug-related problems in Parkinson\u2019s disease: the role of community pharmacists in primary care. Int J Clin Pharm. 2011;33(4):674\u201382.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"1883_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40120-016-0046-4","volume":"5","author":"AA Foppa","year":"2016","unstructured":"Foppa AA, Chemello C, Vargas-Pel\u00e1ez CM, et al. Medication therapy management service for patients with Parkinson\u2019s disease: a before-and-after study. Neurol Ther. 2016;5(1):85\u201399.","journal-title":"Neurol Ther"},{"issue":"27","key":"1883_CR8","doi-asserted-by":"publisher","first-page":"e20758","DOI":"10.1097\/MD.0000000000020758","volume":"99","author":"ZM Yi","year":"2020","unstructured":"Yi ZM, Li TT, Tang QY, et al. Content and impact of pharmacy services for patients with Parkinson\u2019s disease: a systematic review and meta-analysis. Medicine. 2020;99(27):e20758.","journal-title":"Medicine"},{"issue":"6","key":"1883_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1136\/ejhpharm-2020-002356","volume":"29","author":"H Liu","year":"2022","unstructured":"Liu H, Zhong Y, Zeng Z, et al. Drug-related problems in hospitalised Parkinson\u2019s disease patients in China. Eur J Hosp Pharm. 2022;29(6):308\u201312.","journal-title":"Eur J Hosp Pharm"},{"issue":"4","key":"1883_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/ejhpharm-2011-000036","volume":"19","author":"A Shueb","year":"2012","unstructured":"Shueb A. Pharmacist intervention in the management of Parkinson\u2019s disease: evaluating the pharmacist\u2019s intervention at a movement disorders outpatient clinic. Eur J Hosp Pharm. 2012;19(4):355\u20139.","journal-title":"Eur J Hosp Pharm"},{"issue":"1","key":"1883_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11096-015-0206-0","volume":"38","author":"M Henrichsmann","year":"2016","unstructured":"Henrichsmann M, Hempel G. Impact of medication therapy management in patients with Parkinson\u2019s disease. Int J Clin Pharm. 2016;38(1):54\u201360.","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"1883_CR12","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s11096-012-9672-9","volume":"34","author":"S Schr\u00f6der","year":"2012","unstructured":"Schr\u00f6der S, Martus P, Odin P, et al. Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson\u2019s disease. Int J Clin Pharm. 2012;34(5):746\u201356.","journal-title":"Int J Clin Pharm"},{"key":"1883_CR13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1211\/PJ.2009.10967867","volume":"278","author":"G Mynors","year":"2007","unstructured":"Mynors G, Jenkinson C, MacNeill V, et al. A pilot evaluation of specialist community pharmacy services for patients with Parkinson\u2019s disease. The Pharm J. 2007;278:709\u201312.\u00a0","journal-title":"The Pharm J"},{"issue":"15","key":"1883_CR14","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society UPDRS revision task force. Movement disorder society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370.","journal-title":"Mov Disord."},{"issue":"6","key":"1883_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/08870449708406741","volume":"12","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson C, Fitzpatrick R, Peto V, et al. The PDQ-8: development and validation of a short-form Parkinson\u2019s disease questionnaire. Psychol Health. 1997;12(6):805\u201314.","journal-title":"Psychol Health"},{"key":"1883_CR16","unstructured":"National Institute of Mental Health (NIMH). Patient Global Impressions scale\u2014Change, Improvement, Severity (PGI-C, PGI-I, PGI-S). Available at: https:\/\/eprovide.mapi-trust.org\/instruments\/patient-global-impressions-scale-change-improvement-severity. Accessed 13 Nov 2024."},{"key":"1883_CR17","unstructured":"Cipolle RJ, Strand L, Morley P. Drug therapy problems. In: Pharmaceutical care practice: the patient centered approach to medication management services. 3rd ed. New York (NY): Mc Graw Hill; 2012. p. 141\u201382."},{"key":"1883_CR18","first-page":"8692509","volume":"2020","author":"B Sun","year":"2020","unstructured":"Sun B, Wang T, Li N, et al. Analysis of motor complication and relative factors in a cohort of Chinese patients with Parkinson\u2019s disease. Parkinsons Dis. 2020;2020:8692509.","journal-title":"Parkinsons Dis"},{"issue":"7","key":"1883_CR19","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/j.1468-1331.2010.03320.x","volume":"18","author":"F Valldeoriola","year":"2011","unstructured":"Valldeoriola F, Coronell C, Pont C, et al. ADHESON Study Group. Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson\u2019s disease: the ADHESON study. Eur J Neurol. 2011;18(7):980\u20137.","journal-title":"Eur J Neurol."},{"issue":"3 Supp A","key":"1883_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18553\/jmcp.2009.15.s3.1","volume":"15","author":"JJ Chen","year":"2009","unstructured":"Chen JJ, Lew MF, Siderowf A. Treatment strategies and quality-of-care indicators for patients with Parkinson\u2019s disease. J Manag Care Spec Pharm. 2009;15(3 Supp A):1\u201322.\u00a0","journal-title":"J Manag Care Spec Pharm."},{"key":"1883_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2018.08.018","volume":"58","author":"A Makkos","year":"2019","unstructured":"Makkos A, Kov\u00e1cs M, Pint\u00e9r D, et al. Minimal clinically important difference for the historic parts of the unified dyskinesia rating scale. Parkinsonism Relat Disord. 2019;58:79\u201382.","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"1883_CR22","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.parkreldis.2012.09.004","volume":"18","author":"DJ Daley","year":"2012","unstructured":"Daley DJ, Myint PK, Gray RJ, et al. Systematic review on factors associated with medication non-adherence in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2012;18(10):1053\u201361.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"1883_CR23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","volume":"32","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th K, Aschermann Z, Kov\u00e1cs M, et al. Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson\u2019s disease rating scale. Mov Disord. 2017;32(5):789\u201393.","journal-title":"Mov Disord"},{"key":"1883_CR24","doi-asserted-by":"publisher","first-page":"793361","DOI":"10.3389\/fphar.2021.793361","volume":"12","author":"ZM Yi","year":"2022","unstructured":"Yi ZM, Willis S, Zhang Y, et al. Impact of a collaborative pharmaceutical care service for patients with Parkinson\u2019s disease. Front Pharmacol. 2022;12:793361.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1883_CR25","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3233\/JPD-213021","volume":"12","author":"NGM Oonk","year":"2022","unstructured":"Oonk NGM, Movig KLL, van der Palen J, et al. The effect of a structured medication review on quality of life in Parkinson\u2019s disease. J Parkinsons Dis. 2022;12(4):1295\u2013306.","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"1883_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/WNF.0000000000000260","volume":"41","author":"C Stuijt","year":"2018","unstructured":"Stuijt C, Karapinar-\u00c7arkit F, van den Bemt B, et al. Effect of pharmacist-led interventions on (non) motor symptoms, medication-related problems, and quality of life in Parkinson disease patients: a pilot study. Clin Neuropharmacol. 2018;41(1):14\u20139.","journal-title":"Clin Neuropharmacol"},{"key":"1883_CR27","doi-asserted-by":"publisher","first-page":"117172","DOI":"10.1016\/j.jns.2020.117172","volume":"419","author":"K Kurihara","year":"2020","unstructured":"Kurihara K, Nakagawa R, Ishido M, et al. Impact of motor and nonmotor symptoms in Parkinson disease for the quality of life: the Japanese quality-of-life survey of Parkinson disease (JAQPAD) study. J Neurol Sci. 2020;419:117172.","journal-title":"J Neurol Sci"},{"issue":"3","key":"1883_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/cns.13549","volume":"27","author":"N Zhao","year":"2021","unstructured":"Zhao N, Yang Y, Zhang L, et al. Quality of life in Parkinson\u2019s disease: a systematic review and meta-analysis of comparative studies. CNS Neurosci Ther. 2021;27(3):270\u20139.","journal-title":"CNS Neurosci Ther"},{"key":"1883_CR29","doi-asserted-by":"publisher","first-page":"1149615","DOI":"10.3389\/fneur.2023.1149615","volume":"14","author":"A Kakimoto","year":"2023","unstructured":"Kakimoto A, Kawazoe M, Kurihara K, et al. Impact of non-motor fluctuations on QOL in patients with Parkinson\u2019s disease. Front Neurol. 2023;14:1149615.","journal-title":"Front Neurol"},{"key":"1883_CR30","doi-asserted-by":"publisher","unstructured":"Dashtipour K, Chen J, Dalaie P, et al. Correlation between unified Parkinson\u2019s disease rating scale and global impression of change scales (P1.198). Neurology. 2015;84(14 Suppl). Available at: https:\/\/doi.org\/10.1212\/WNL.84.14_supplement.P1.198. Accessed 13 Nov 2024.","DOI":"10.1212\/WNL.84.14_supplement.P1.198"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01883-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01883-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01883-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:36:39Z","timestamp":1748586999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01883-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1883"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01883-6","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No specific funding was received.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}